Since adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive breast cancer [85], the JACOB trial was recently conducted to evaluate the same strategy in untreated HER2-positive GC. This evidence concerns the gene ERBB2 and breast cancer.